Novartis Science

The voice of research and development @Novartis. See our guidelines:

[Novartis Science @NovartisScience]

@ghozwill @ghozwill we're sorry to hear this & would like to look into it further, please send your contact details to [email protected]

[Novartis Science @NovartisScience]

@cokacokicoklat @cokacokicoklat Thank you for your enquiry. For product related information we recommend you contact our local office in Indonesia by phone at [phone]. For additional contact information, visit this page: https://t.co/Kc21XTghw7

[Novartis Science @NovartisScience]

A new paper sheds light on how the transcription factor BACH1 regulates the oxidative stress response, offering mechanistic insights into a key cellular pathway and potential target in oxidative stress-related diseases such as cancer, autoimmune disorders. https://t.co/hsT3c7sEJf

[Novartis Science @NovartisScience]

Novartis, @bioagelabs announce multi-year collaboration to discover novel targets for therapies that address age-related diseases and conditions.

[Novartis Science @NovartisScience]

@HDCureToday Dear HD Cure Today,
Thank you for your message. We recommend you contact our local office for this matter. You can find contact details using the location finder on our website: https://t.co/o6kEOgdOpV
Kind regards,
Novartis Community Manager

[Novartis Science @NovartisScience]

Novartis has entered into a global license and collaboration agreement with @PTCBio for a Huntington’s disease program, currently in Phase II development, with the potential to become the first oral disease-modifying therapy for the disorder. https://t.co/hUhC2zCxoS

[Novartis News @NovartisNews]

Novartis has acquired Kate Therapeutics, a preclinical stage biotechnology company focused on developing adeno-associated virus (AAV)-based gene therapies to treat genetically defined neuromuscular diseases. https://t.co/yNNQGoEst9

[Novartis Science @NovartisScience]

Novartis and @RatioTx have entered a license and collaboration agreement to advance a next-generation radioligand therapy to bring additional therapeutic options forward for patients with hard-to-treat cancer. https://t.co/EHir57qnjZ

[Novartis Science @NovartisScience]

Novartis and Schrödinger have announced a multi-target research collaboration, and an expanded software agreement that will broaden Novartis access to Schrödinger’s computational predictive modeling technology and enterprise informatics platform. https://t.co/Tw8GifOaW8

[Novartis Science @NovartisScience]

Novartis, @MonteRosaTx announce an exclusive global development and commercialization license agreement to advance molecular glue degraders, including an investigational program currently in Phase 1 clinical development. https://t.co/uQucA826Ty

[Novartis Science @NovartisScience]

Novartis Biomedical Research and the @dundeeuni Drug Discovery Unit (DDU) are collaborating to advance drugs to help address global health challenges, including an antimalarial that targets dormant parasites, and an anti-viral for pandemic preparedness. https://t.co/UvRbhFv7qW

[Novartis Science @NovartisScience]

In @NatureMicrobiol, researchers describe a potential pediatric drug candidate for #cryptosporidiosis, a neglected disease that causes severe diarrhea, prolonged illness, and even death in young children and other vulnerable populations worldwide. https://t.co/ORTH2VgE5L

[Novartis Science @NovartisScience]

The President of Novartis Biomedical Research, @FionaHMarshall, talks about curiosity and collaboration, and her focus on developing “platforms for productivity” that build upon company successes to produce a robust portfolio of medicines for patients. https://t.co/60ZEagOXEH.

[Novartis Science @NovartisScience]

Novartis and Versant Ventures launch Borealis Biosciences, a discovery-stage biotech focused on developing next-generation RNA medicines for kidney diseases. https://t.co/2GgFkNGjkX

[Novartis Science @NovartisScience]

Novartis, Dren Bio sign collaboration agreement to discover, advance antibody-based immune cell engagers for certain cancers, building on Novartis efforts to explore a range of modalities and approaches to bring transformative therapies forward for patients.

[Novartis Science @NovartisScience]

Applications are being accepted for the Novartis Data Science Innovation Fellowship Program. If you are a recent PhD grad with a passion for #datascience & #AI and are interested in a career helping patients by advancing #drugdiscovery, apply by July 29.

[Novartis Science @NovartisScience]

Our researchers share a new approach for the potential treatment of #sicklecelldisease: using molecular glue degraders to break down a novel protein that suppresses fetal hemoglobin levels. Read their paper in @ScienceMagazine

[Novartis Science @NovartisScience]

In @aplbioeng, Novartis researchers unveil a new device that enables high-throughput screening of stretched cells to better understand how they respond under mechanical stress and inform drug discovery. #mechanobiology

[Novartis Science @NovartisScience]

Novartis, PeptiDream have entered into an agreement to expand their discovery collaboration aimed at identifying novel peptides for potential use in radioligand therapy and other contexts
https://t.co/wrzfUd5EYk

[Novartis Science @NovartisScience]

Yesterday, Novartis and @MedsforMalaria announced positive data from the CALINA study exploring a potential medicine formulated for the smallest babies with #malaria, for whom there is currently no evidence-based treatment.